<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Management of hyperphosphatemia in adults with chronic kidney disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Management of hyperphosphatemia in adults with chronic kidney disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Management of hyperphosphatemia in adults with chronic kidney disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            L Darryl Quarles, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey S Berns, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric N Taylor, MD, MSc, FASN
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 04, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The tendency toward phosphate retention develops early in chronic kidney disease (CKD) due to the reduction in the filtered phosphate load. Overt hyperphosphatemia develops when the estimated glomerular filtration rate (eGFR) falls below 25 to 40 mL/min/1.73 m
         <sup>
          2
         </sup>
         [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p>
         Hyperphosphatemia has been associated with increased mortality and morbidity [
         <a href="#rid4">
          4-10
         </a>
         ].
        </p>
        <p>
         This topic reviews recommendations regarding target phosphate concentration and treatment options for hyperphosphatemia for patients with CKD.
        </p>
        <p>
         Recommended goals for serum parathyroid hormone (PTH) concentration for patients with CKD are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">
          "Management of secondary hyperparathyroidism in adult patients on dialysis", section on 'Treat high parathyroid hormone'
         </a>
         .)
        </p>
        <p>
         Mechanisms underlying the physiologic response to phosphate retention are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">
          "Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H169676142">
         <span class="h1">
          MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         , we routinely monitor serum phosphate, calcium, intact parathyroid hormone (iPTH), and 25-hydroxyvitamin D levels.
        </p>
        <p>
         The frequency with which these measurements are performed depends on the eGFR and whether baseline abnormalities are present or therapeutic measures have been taken. In addition, monitoring may be performed more frequently if the eGFR is rapidly decreasing. Values should be rechecked if kidney function worsens.
        </p>
        <p>
         The following monitoring schedule is reasonable and based upon the 2017 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H521842278">
         <span class="h2">
          Estimated GFR 30 to 59 mL/min/1.73 m2
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with estimated glomerular filtration rate (eGFR) 30 to 59 mL/min/1.73 m
         <sup>
          2
         </sup>
         , we measure serum phosphate and calcium every 6 to 12 months. We measure iPTH at least every 12 months and every 6 months if the baseline concentration is elevated or if the patient is being treated. We measure 25-hydroxyvitamin D every 12 months and every 6 months if the patient is being treated.
        </p>
        <p class="headingAnchor" id="H195677">
         <span class="h2">
          Estimated GFR 15 to 29 mL/min/1.73 m2
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with estimated glomerular filtration rate (eGFR) 15 to 29 mL/min/1.73 m
         <sup>
          2
         </sup>
         , we measure serum phosphate and calcium every three to six months. We measure iPTH every 6 to 12 months and every 6 months if the baseline concentration is elevated or if the patient is being treated. We measure 25-hydroxyvitamin D every 12 months and every 6 months if the patient is being treated for vitamin D deficiency.
        </p>
        <p class="headingAnchor" id="H521842284">
         <span class="h2">
          Estimated GFR &lt;15 mL/min/1.73 m2 (including patients on dialysis)
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with estimated glomerular filtration rate (eGFR) &lt;15 mL/min/1.73 m
         <sup>
          2
         </sup>
         , we measure serum phosphate and calcium every one to three months. We measure iPTH every three to six months and every three months if the baseline concentration is elevated or if the patient is being treated. We measure 25-hydroxyvitamin D every 12 months and every 6 months if the patient is being treated for vitamin D deficiency.
        </p>
        <p class="headingAnchor" id="H89991780">
         <span class="h1">
          TREATMENT APPROACH
         </span>
        </p>
        <p class="headingAnchor" id="H89993305">
         <span class="h2">
          Patients with nondialysis chronic kidney disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with nondialysis CKD, we try to maintain the serum phosphate level in the normal range (ie, &lt;4.5 mg/dL [1.45 mmol/L]) with dietary modification; this level is consistent with the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines [
         <a href="#rid11">
          11-13
         </a>
         ]. We only use phosphate binders when the serum phosphate level is persistently elevated &gt;5.5 mg/dL despite dietary restriction [
         <a href="#rid12">
          12,14-16
         </a>
         ]. In patients who present with very high phosphate (ie, &gt;6 mg/dL), we start phosphate binders concurrently with dietary restriction because it is unlikely that dietary restriction alone will be effective. The selection of type of phosphate binder is the same for patients on dialysis and those with nondialysis CKD and is discussed below. (See
         <a class="local">
          'Specific treatment'
         </a>
         below.)
        </p>
        <p>
         We suggest a moderate restriction of phosphate intake (approximately 900 mg/day) in patients with nondialysis CKD, provided that this can be done without compromising nutritional status  (
         <a class="graphic graphic_table graphicRef79877 graphicRef56081" href="/z/d/graphic/79877.html" rel="external">
          table 1A-B
         </a>
         ). These recommendations are consistent with the Kidney Disease Outcomes Quality Initiative (KDOQI) and KDIGO guidelines [
         <a href="#rid11">
          11,12,14
         </a>
         ]. (See
         <a class="local">
          'Phosphate restriction'
         </a>
         below.)
        </p>
        <p>
         We do not attempt to reduce phosphate to lower than normal values or prevent an increase in serum phosphate among patients who have a normal phosphate concentration.
        </p>
        <p>
         Studies examining the association of hyperphosphatemia with mortality have shown mixed results. A predominant number of studies report an increased mortality in association with hyperphosphatemia among patients with nondialysis CKD [
         <a href="#rid10">
          10,17-21
         </a>
         ]. This was best illustrated in a meta-analysis of three studies with nearly 5000 patients with nondialysis CKD, which showed a 35 percent increase in mortality per mg increase in phosphate above normal values (95% CI 1.16-1.57) [
         <a href="#rid10">
          10
         </a>
         ]. The median follow-up in individual studies was approximately one to two years. In one study (which was included in the meta-analysis), serum phosphate &gt;3.5 mg/dL (1.13 mmol/L) was an independent predictor of all-cause mortality [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         Hyperphosphatemia is a stimulus for hyperparathyroidism. Studies also suggest that there is progressive cardiovascular risk associated with hyperphosphatemia in patients with normal kidney function, as well in patients with CKD with estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         who are not on dialysis [
         <a href="#rid17">
          17,20,22,23
         </a>
         ].
        </p>
        <p>
         Some other studies have not demonstrated an association between serum phosphate and mortality among patients with nondialysis CKD [
         <a href="#rid24">
          24,25
         </a>
         ]. One study published after the cited meta-analysis did not show an association between quartiles of serum phosphate and mortality over a mean follow-up of over two years [
         <a href="#rid24">
          24
         </a>
         ]. Differences in study populations are a likely reason for the discrepancy between studies [
         <a href="#rid3">
          3
         </a>
         ]. As an example, individuals in the later study had much milder kidney dysfunction (with mean eGFR of 44 to 48 mL/min/1.73 m
         <sup>
          2
         </sup>
         ) compared with prior studies.
        </p>
        <p>
         The effect of phosphate binders on serum phosphate levels can be variable, and the prescription of a phosphate binder increases the patient's pill burden. In a randomized trial, compared with placebo, the use of phosphate binders was associated with a greater decrease in serum phosphate and in 24-hour urine phosphate at three, six, and nine months, although the effect was small [
         <a href="#rid26">
          26
         </a>
         ]. In addition, the use of phosphate binders was associated with a stable parathyroid hormone (PTH) value versus an increase in the placebo group. In another trial, use of a phosphate binder (
         <a class="drug drug_general" data-topicid="10261" href="/z/d/drug information/10261.html" rel="external">
          sevelamer
         </a>
         ) led to no improvement in serum phosphate [
         <a href="#rid27">
          27
         </a>
         ]. In addition, no intervention to lower serum phosphate (dietary restriction or use of phosphate binders) has been shown to affect clinically important outcomes among patients with nondialysis CKD [
         <a href="#rid27">
          27,28
         </a>
         ]. Thus, some experts do not recommend phosphate binders.
        </p>
        <p>
         An additional concern is that calcium-containing phosphate binders may induce positive calcium balance in patients with CKD, which could lead to vascular calcification. (See
         <a class="local">
          'Specific treatment'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H89993311">
         <span class="h2">
          Patients on dialysis
         </span>
        </p>
        <p class="headingAnchor" id="H4093647767">
         <span class="h3">
          Initial therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most patients on dialysis, we try to maintain the serum phosphate concentration between 3.5 and 5.5 mg/dL (1.13 and 1.78 mmol/L), although there are no data that this improves outcomes. Serum phosphate &gt;5.5 mg/dL (1.78 mmol/L) is an indication for treatment.
        </p>
        <p>
         Increased serum phosphate is associated with increased mortality among patients on dialysis [
         <a href="#rid4">
          4-10
         </a>
         ]. This was best shown in a meta-analysis of 12 studies that included 92,345 patients with CKD, over 97 percent of whom were on dialysis [
         <a href="#rid10">
          10
         </a>
         ]. Among 10 studies that were perceived to be adequately adjusted (in which seven studies were of patients on dialysis), serum phosphate &gt;5.5 mg/dL (1.78 mmol/L) was associated with increased mortality. Based upon 13 studies that reported a continuous relative risk for each mg/dL increase in phosphate, the mortality risk increased by 18 percent (95% CI 1.12-1.25).
        </p>
        <p>
         A target phosphate goal between 3.5 and 5.5 mg/dL (1.13 and 1.78 mmol/L) is consistent with the KDOQI guidelines [
         <a href="#rid14">
          14
         </a>
         ]. This target differs from the more recent KDIGO guidelines, which recommend lowering levels toward the normal range but do not specify a target threshold [
         <a href="#rid11">
          11,12
         </a>
         ]. We feel that the KDIGO recommendations do not provide a practical goal.
        </p>
        <p>
         The initial therapy includes phosphate restriction and phosphate binders [
         <a href="#rid12">
          12,29
         </a>
         ].
        </p>
        <p>
         We suggest a moderate restriction of phosphate intake in patients on dialysis, provided that this can be done without compromising nutritional status. These recommendations are consistent with the KDOQI and KDIGO guidelines [
         <a href="#rid11">
          11,14
         </a>
         ].
        </p>
        <p>
         We restrict dietary phosphate to 900 mg/day. Among patients on dialysis, phosphate restriction should be done under the supervision of a dietician. This is because many patients on dialysis have either overt or borderline malnutrition. For such patients, protein supplementation (which contributes to phosphorus intake) rather than protein restriction is the goal. In this setting, the patient should be encouraged to avoid unnecessary dietary phosphate (such as phosphate-containing food additives, dairy products, certain vegetables, many processed foods, and colas), while increasing the intake of high-biologic-value sources of protein (such as meat and eggs) [
         <a href="#rid30">
          30,31
         </a>
         ]. (See
         <a class="local">
          'Phosphate restriction'
         </a>
         below.)
        </p>
        <p>
         While we may try dietary restriction first and only use a phosphate binder if the phosphate is persistently and progressively elevated after one or two months of dietary phosphorus restriction, most patients will also require a phosphate binder. Many clinicians will start dietary phosphate restriction and phosphate binders simultaneously in all patients with hyperphosphatemia.
        </p>
        <p>
         Two observational studies have suggested that phosphate binders are associated with decreased mortality among patients on dialysis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a prospective, observational study of patients on incident dialysis followed for one year, the use of phosphate binders was associated with a 25 percent lower one-year mortality [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 6797 patients enrolled in an observational, prospective study (Current Management of Secondary Hyperparathyroidism: A Multicenter Observational Study [COSMOS]), patients prescribed phosphate binders had a 29 percent lower risk of all-cause mortality and a 22 percent lower risk of cardiovascular mortality [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Randomized trials are needed to determine whether the use of phosphate binders provides a benefit on clinically important endpoints among patients on dialysis.
        </p>
        <p>
         The choice of phosphate binder is discussed below. (See
         <a class="local">
          'Specific treatment'
         </a>
         below.)
        </p>
        <p>
         In addition to phosphate restriction and binders, it is important to make sure patients are adequately dialyzed and achieving recommended Kt/V targets. (See
         <a class="medical medical_review" href="/z/d/html/1836.html" rel="external">
          "Prescribing and assessing adequate hemodialysis"
         </a>
         .)
        </p>
        <p>
         However, in patients who are undergoing standard in-center hemodialysis (which represents most patients on hemodialysis), we do not generally increase the dialysis above the recommended dose, as this has not been shown to improve clinically important outcomes.
        </p>
        <p>
         Although an exception may be made for exceptionally motivated patients who may be willing to undergo more dialysis, most patients find it difficult to increase the dialysis time sufficiently to reduce the serum phosphate. Standard dialysis (ie, three times weekly for four hours per session) is limited in its ability to remove phosphate. The average standard dialysis session removes approximately 900 mg of phosphate.
        </p>
        <p>
         Some patients may consider daily or nocturnal (ie, usually prolonged and nightly) hemodialysis. Frequent or prolonged hemodialysis leads to greater removal of phosphate and can substantially lower serum phosphate levels. In fact, in some patients undergoing frequent or prolonged hemodialysis, serum phosphate can be controlled without the use of phosphate binders. However, many factors impact a decision to undergo daily dialysis, and hyperphosphatemia alone is rarely the deciding factor. (See
         <a class="medical medical_review" href="/z/d/html/1898.html" rel="external">
          "Short daily hemodialysis", section on 'Phosphate'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1959.html" rel="external">
          "Outcomes associated with nocturnal hemodialysis", section on 'Phosphate'
         </a>
         .)
        </p>
        <p>
         Occasionally, hyperphosphatemia will be refractory to these methods. (See
         <a class="local">
          'Refractory hyperphosphatemia'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H449863857">
         <span class="h3">
          Refractory hyperphosphatemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients on dialysis, hyperphosphatemia is occasionally refractory to dietary restriction and phosphate binders (see
         <a class="local">
          'Specific treatment'
         </a>
         below), and patients may be unwilling or unable to undergo frequent or prolonged hemodialysis.
        </p>
        <p>
         In such patients, our stepwise approach is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Optimize treatment of hyperparathyroidism
         </strong>
         – The treatment of hyperparathyroidism should be reviewed. Both inadequately treated hyperparathyroidism and the use of high doses of
         <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">
          calcitriol
         </a>
         or active vitamin D analogs may contribute to hyperphosphatemia through different mechanisms. High levels of PTH increase bone resorption and the release of phosphate from bone [
         <a href="#rid34">
          34
         </a>
         ] and active vitamin D moieties increase the gastrointestinal absorption of phosphate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among such patients, the phosphate may be reduced by decreasing PTH using calcimimetics instead of
         <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">
          calcitriol
         </a>
         or vitamin D analogs. In select patients with uncontrolled severe hyperparathyroidism, parathyroidectomy may be indicated, although this is rare. (See
         <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">
          "Management of secondary hyperparathyroidism in adult patients on dialysis", section on 'Refractory hyperparathyroidism'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1838.html" rel="external">
          "Refractory hyperparathyroidism and indications for parathyroidectomy in adult patients on dialysis", section on 'Symptomatic patients'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Add
         </strong>
         <a class="drug drug_general" data-topicid="122582" href="/z/d/drug information/122582.html" rel="external">
          tenapanor
         </a>
         <strong>
          to the medical regimen
         </strong>
         – In adequately dialyzed patients who have serum phosphate levels persistently &gt;5.5 mg/dL despite dietary restriction, optimal treatment of hyperparathyroidism, and the appropriate use of phosphate binders (see
         <a class="local">
          'Specific treatment'
         </a>
         below), we suggest adding tenapanor to the medical regimen. Tenapanor is an inhibitor of intestinal sodium/hydrogen exchanger 3 (NHE3) that was developed to treat irritable bowel syndrome with constipation but was also found to lower serum phosphate by blocking its paracellular transport from the intestinal lumen [
         <a href="#rid35">
          35
         </a>
         ]. Since no data demonstrate that lowering phosphate levels to 5.5 mg/dL or below improves clinical outcomes, some experts use higher levels of serum phosphate (eg, &gt;6.5 mg/dL) as a threshold for tenapanor add-on therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The usual dose range of
         <a class="drug drug_general" data-topicid="122582" href="/z/d/drug information/122582.html" rel="external">
          tenapanor
         </a>
         is 10 to 30 mg twice daily, taken before the first and last meals of the day. The major adverse effect of tenapanor is an increase in stool frequency, thought to be due to an increase in stool water content. Diarrhea occurs in approximately half of tenapanor-treated patients [
         <a href="#rid36">
          36
         </a>
         ] but is usually not severe; diarrhea leads to drug discontinuation in approximately five percent of patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients on hemodialysis, multiple trials have demonstrated that
         <a class="drug drug_general" data-topicid="122582" href="/z/d/drug information/122582.html" rel="external">
          tenapanor
         </a>
         lowers phosphate to a modest degree [
         <a href="#rid37">
          37-42
         </a>
         ]. In a meta-analysis of randomized trials, tenapanor therapy compared with placebo resulted in a mean decrease in serum phosphorus of 1.79 mg/dL [
         <a href="#rid36">
          36
         </a>
         ]. In one representative trial, 169 patients on hemodialysis with hyperphosphatemia despite treatment with one or more phosphate binders were randomized to tenapanor or placebo; phosphate binders were continued in both groups [
         <a href="#rid41">
          41
         </a>
         ]. Patients treated with tenapanor had a serum phosphorus 1.76 mg/dL lower than patients in the placebo group. Diarrhea occurred in 63.1 percent and 14.1 percent of patients in the tenapanor and placebo groups, respectively, but was reported as mild or moderate in all cases.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H169682201">
         <span class="h2">
          Specific treatment
         </span>
        </p>
        <p class="headingAnchor" id="H4073137610">
         <span class="h3">
          Phosphate restriction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dietary phosphate restriction can be effective in reducing the serum phosphate concentration [
         <a href="#rid31">
          31
         </a>
         ], although the effect is inconsistent, and interventions designed to reduce dietary phosphate intake may have minimal effects on serum and urinary phosphate concentrations [
         <a href="#rid43">
          43,44
         </a>
         ]. Moreover, no adequately powered studies have examined the efficacy of dietary phosphate restrictions on patient-important outcomes.
        </p>
        <p>
         Approximately 900 mg/day of dietary phosphate is a level that at least some patients will find acceptable. Phosphate restriction should primarily include processed foods and colas and
         <strong>
          not
         </strong>
         high-biologic-value foods such as meat and eggs  (
         <a class="graphic graphic_table graphicRef79877 graphicRef56081" href="/z/d/graphic/79877.html" rel="external">
          table 1A-B
         </a>
         ). Food additives (as are found in processed foods) and medications are an important source of dietary phosphate [
         <a href="#rid45">
          45
         </a>
         ]. In addition to having high phosphate content, processed foods provide a more easily absorbed form of phosphate compared with fresh animal- and plant-based foods [
         <a href="#rid30">
          30,46
         </a>
         ]. We agree with the KDIGO guidelines that patients should receive education on the absorbability of phosphate from different food [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         Some nephrologists recommend a more vegetarian-based diet in order to control phosphate. Phosphate bioavailability may be less with a vegetarian diet compared with an animal protein-based diet [
         <a href="#rid47">
          47
         </a>
         ]. Many foods that have traditionally been labeled high phosphate (such as beans and nuts) may actually be acceptable (providing they are not too high in potassium) because phosphate from these sources is absorbed slowly [
         <a href="#rid11">
          11,46
         </a>
         ]. This is because plant-derived phosphate found in unprocessed foods is in the form of phytate phosphorus, and the human intestine does not secrete phytase, the enzyme required for absorption [
         <a href="#rid30">
          30
         </a>
         ]. In addition, such a diet rich in legumes, nuts, and whole grains may also result in higher fiber intake while offering wider food choices [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         A randomized study of patients on hemodialysis showed that careful instruction on avoiding foods with phosphorus additives resulted in larger declines in serum phosphate compared with control patients who did not receive such instruction [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         Very few studies have examined the efficacy of dietary phosphate restrictions on patient-important outcomes among patients on dialysis. In a post hoc analysis of data from the Hemodialysis (HEMO) study, prescribed phosphate restriction was not associated with improved survival of patients on hemodialysis [
         <a href="#rid48">
          48
         </a>
         ]. In fact, there was a stepwise trend toward better survival with less restrictive prescribed phosphate intake in this study. However, the HEMO study was performed prior to an awareness of the importance of food additives as a source of phosphate; as a result, phosphate restriction may have been achieved by the restriction of nutritionally beneficial food. Supporting this possibility, phosphate restriction tended to be associated with poorer nutritional indices and a persistently greater need for nutritional supplementation in this study.
        </p>
        <p class="headingAnchor" id="H1687951240">
         <span class="h3">
          Phosphate binders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Phosphate binders are categorized as calcium-containing and non-calcium-containing. Calcium-containing binders include
         <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">
          calcium carbonate
         </a>
         and
         <a class="drug drug_general" data-topicid="9184" href="/z/d/drug information/9184.html" rel="external">
          calcium acetate
         </a>
         . Major non-calcium-containing binders include
         <a class="drug drug_general" data-topicid="10261" href="/z/d/drug information/10261.html" rel="external">
          sevelamer
         </a>
         and
         <a class="drug drug_general" data-topicid="10219" href="/z/d/drug information/10219.html" rel="external">
          lanthanum
         </a>
         . Other agents include
         <a class="drug drug_general" data-topicid="96959" href="/z/d/drug information/96959.html" rel="external">
          ferric citrate
         </a>
         and
         <a class="drug drug_general" data-topicid="91795" href="/z/d/drug information/91795.html" rel="external">
          sucroferric oxyhydroxide
         </a>
         . All are equivalently effective in lowering phosphate [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         For most patients, we suggest that non-calcium-containing binders be used. Exceptions may be made where non-calcium-containing binders are not available or affordable or when the serum calcium is low and PTH is elevated, such as in patients concomitantly treated with calcimimetics. However many experts argue that calcium-containing binders should be avoided in all patients [
         <a href="#rid11">
          11
         </a>
         ]. Dosing of these agents is presented below. (See
         <a class="local">
          'Dose and specific agents'
         </a>
         below.)
        </p>
        <p>
         A number of trials and two meta-analyses have suggested that non-calcium-containing phosphate binders, compared with calcium-containing phosphate binders, decrease mortality among patients with CKD [
         <a href="#rid49">
          49-59
         </a>
         ].
        </p>
        <p>
         A meta-analysis of 11 open-label, randomized trials (4622 patients) revealed a 22 percent decrease in all-cause mortality among patients randomly assigned to receive non-calcium-based binders (
         <a class="drug drug_general" data-topicid="10261" href="/z/d/drug information/10261.html" rel="external">
          sevelamer
         </a>
         , 10 studies including 3268 patients, or lanthanum, one study including 1354 patients) compared with calcium-based binders (relative risk [RR] 0.78, 95% CI 0.61-0.98) [
         <a href="#rid60">
          60
         </a>
         ]. The results of this meta-analysis were driven in large part by the study that used
         <a class="drug drug_general" data-topicid="10219" href="/z/d/drug information/10219.html" rel="external">
          lanthanum carbonate
         </a>
         not sevelamer. Analysis of patients on dialysis and those with nondialysis CKD showed similar reductions in mortality. Most studies in this meta-analysis were limited to 24 months. Analysis of studies with follow-up at 36 and 42 months showed no difference in mortality [
         <a href="#rid60">
          60
         </a>
         ]. This analysis did not look at cardiovascular mortality.
        </p>
        <p>
         A second meta-analysis also reported a decrease in all-cause mortality with
         <a class="drug drug_general" data-topicid="10261" href="/z/d/drug information/10261.html" rel="external">
          sevelamer
         </a>
         compared with calcium-based binders (13 studies, n = 3799, RR 0.54, 95% CI 0.32-0.93) [
         <a href="#rid61">
          61
         </a>
         ]. There was no reduction in cardiovascular mortality demonstrated (four studies, n = 2712, RR 0.33, 95% CI 0.07-1.64). Patients receiving sevelamer had lower cholesterol, low-density lipoprotein (LDL)-cholesterol, calcium, and decreased risk of hypercalcemia. There was no difference between groups in serum phosphate. There was considerable heterogeneity among the studies.
        </p>
        <p>
         However, a large, observational cohort study of over 4000 older patients on incident dialysis found that the risk of fatal or nonfatal cardiovascular events or all-cause mortality was not different among patients treated with either
         <a class="drug drug_general" data-topicid="10261" href="/z/d/drug information/10261.html" rel="external">
          sevelamer
         </a>
         or
         <a class="drug drug_general" data-topicid="9184" href="/z/d/drug information/9184.html" rel="external">
          calcium acetate
         </a>
         [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
         In addition to the possible effects on mortality, calcium-containing binders, but not non-calcium-containing binders, are associated with hypercalcemia, adynamic bone disease, and vascular calcification, all which could result in increased morbidity [
         <a href="#rid26">
          26,49,51,53,54,61,63
         </a>
         ].
        </p>
        <p>
         Even in the absence of hypercalcemia, a positive calcium balance may increase vascular calcification. Because normal dietary calcium intake is roughly 1000 mg per day, prescription of 1500 mg elemental calcium per day (ie,
         <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">
          calcium carbonate
         </a>
         1250 mg three times daily with meals) increases calcium ingestion by roughly 2.5-fold. In addition, calcium excretion is reduced in CKD because of a reduced filtered load of calcium. The combination of increased calcium ingestion and decreased calcium excretion could lead to positive calcium balance, even in the absence of hypercalcemia. This was demonstrated in a well-conducted randomized, placebo-controlled crossover study that examined the effect of oral calcium carbonate administration on calcium and phosphate balance in eight patients with CKD with a mean eGFR of 15 to 59 mL/min/1.73 m
         <sup>
          2
         </sup>
         [
         <a href="#rid64">
          64
         </a>
         ]. Subjects received a controlled diet with either a calcium carbonate supplement (1500 mg/day calcium) or placebo during two three-week balance periods. Fasting blood and urine were collected at baseline and at the end of each week. All feces and urine were collected during weeks 2 and 3 of each balance period.
        </p>
        <p>
         An oral and intravenous calcium isotope (
         <sup>
          45
         </sup>
         CaCl
         <sub>
          2
         </sub>
         ) was administered to determine calcium kinetics. Patients were in neutral calcium and phosphorus balance while on the placebo.
         <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">
          Calcium carbonate
         </a>
         supplementation caused a positive calcium balance and had no effect on phosphorus balance. In addition, compared with placebo, calcium carbonate supplementation produced a small reduction in urine phosphorus excretion.
        </p>
        <p>
         Calcium kinetics demonstrated positive net bone balance. However, the amount of calcium that was deposited in bone was less than the overall positive calcium balance, suggesting that some degree of soft-tissue deposition occurred. Fasting blood and urine biochemistries of calcium and phosphate homeostasis were unaffected by
         <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">
          calcium carbonate
         </a>
         , suggesting that it is futile to rely solely on blood concentrations to determine mineral excess or accumulation.
        </p>
        <p>
         The interpretation of these data may be limited by the short-term nature of the study. It is possible that patients were not in steady state after only one week of calcium administration. If so, the short-term positive calcium balance that was observed may have been an appropriate response to correct years of bone calcium depletion and thus may decrease over time [
         <a href="#rid65">
          65
         </a>
         ]. In studies of longer duration in predialysis CKD, 24-hour phosphate excretion substantially declined when calcium-containing binders were used [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4094257203">
         <span class="h3">
          Dose and specific agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         For all phosphate buffers, the lowest dose that is effective should be used. If calcium-containing buffers are selected, we suggest that the total dose of elemental calcium (including dietary sources) not exceed 2000 mg per day [
         <a href="#rid14">
          14
         </a>
         ]. The amount of elemental calcium contained in the phosphate binder should not exceed 1500 mg per day. This is consistent with both the KDOQI and KDIGO guidelines [
         <a href="#rid12">
          12-14
         </a>
         ].
        </p>
        <p>
         Phosphate binders are only effective if taken with meals [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
         Specific agents are discussed here.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sevelamer
         </strong>
         <strong>
          –
         </strong>
         <a class="drug drug_general" data-topicid="10261" href="/z/d/drug information/10261.html" rel="external">
          Sevelamer
         </a>
         hydrochloride (Renagel) and sevelamer carbonate (Renvela) are nonabsorbable cationic polymers that bind phosphate through ion exchange [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="10261" href="/z/d/drug information/10261.html" rel="external">
          Sevelamer
         </a>
         is effective in lowering serum phosphate levels [
         <a href="#rid51">
          51,52,68-75
         </a>
         ]. The usual dose range of sevelamer is 800 to 2400 mg three times daily with meals.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="10261" href="/z/d/drug information/10261.html" rel="external">
          Sevelamer
         </a>
         hydrochloride, but not sevelamer carbonate, may induce metabolic acidosis. For this reason, sevelamer carbonate is preferred over sevelamer hydrochloride in patients with nondialysis CKD and in any patient with metabolic acidosis. (See
         <a class="medical medical_review" href="/z/d/html/2293.html" rel="external">
          "Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="10261" href="/z/d/drug information/10261.html" rel="external">
          Sevelamer
         </a>
         is much more expensive than calcium-containing phosphate binders [
         <a href="#rid76">
          76,77
         </a>
         ]. By one estimate in the United States, approximately 780 million dollars would be required per year in order to provide sevelamer to all who met KDOQI criteria for its use [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lanthanum
         </strong>
         <strong>
          –
         </strong>
         <a class="drug drug_general" data-topicid="10219" href="/z/d/drug information/10219.html" rel="external">
          Lanthanum
         </a>
         is a rare-earth element that is effective in lowering phosphate levels in patients on dialysis [
         <a href="#rid78">
          78-85
         </a>
         ] and patients with nondialysis CKD [
         <a href="#rid86">
          86
         </a>
         ]. Compared with calcium-containing phosphate binders, lanthanum appears to be associated with lower incidences of oversuppression of PTH levels [
         <a href="#rid78">
          78-80,82,84,85,87-89
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An additional benefit of
         <a class="drug drug_general" data-topicid="10219" href="/z/d/drug information/10219.html" rel="external">
          lanthanum
         </a>
         , compared with other phosphate binders, may be a reduced daily tablet burden [
         <a href="#rid90">
          90
         </a>
         ]. In addition, lanthanum tablets are chewed rather than swallowed whole. The usual dose range of lanthanum is 500 to 1000 mg three times daily with meals.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In studies of patients on dialysis, no significant adverse effects have been reported with
         <a class="drug drug_general" data-topicid="10219" href="/z/d/drug information/10219.html" rel="external">
          lanthanum
         </a>
         [
         <a href="#rid78">
          78-80,82,84,85,87-89
         </a>
         ]. The safety of lanthanum administered for up to two years was evaluated in 1359 patients on hemodialysis randomly assigned to lanthanum (maximum dose of 3000 mg/day) or their prestudy phosphate binder [
         <a href="#rid84">
          84
         </a>
         ]. The incidence of adverse effects was similar in both groups, which principally consisted of gastrointestinal effects. No evidence of hepatic toxicity was observed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Calcium-containing binders
         </strong>
         – Calcium-containing phosphate binders include
         <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">
          calcium carbonate
         </a>
         and
         <a class="drug drug_general" data-topicid="9184" href="/z/d/drug information/9184.html" rel="external">
          calcium acetate
         </a>
         [
         <a href="#rid91">
          91-93
         </a>
         ]. Calcium acetate may be a more efficient phosphate binder than calcium carbonate [
         <a href="#rid94">
          94-96
         </a>
         ]. However, for most patients we suggest that non-calcium-containing binders be used. (See
         <a class="local">
          'Phosphate binders'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The usual dosage range for
         <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">
          calcium carbonate
         </a>
         is 1250 to 3750 mg per day in divided doses with meals. The usual dose range for
         <a class="drug drug_general" data-topicid="9184" href="/z/d/drug information/9184.html" rel="external">
          calcium acetate
         </a>
         is 1334 to 2001 mg three times daily with meals. The higher ends of these usual dose ranges represent approximately 1500 mg daily of elemental calcium. Because dietary calcium intake is typically on the order of 1000 mg per day, patients taking calcium-containing binders at the high end of the usual dosage range may have total daily intakes of elemental calcium that exceed the recommended level of 2000 mg per day.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As noted above, calcium-containing phosphate binders may lead to extraskeletal calcium phosphate deposition, particularly in the setting of hyperphosphatemia [
         <a href="#rid91">
          91,97-102
         </a>
         ]. Combined hypercalcemia and hyperphosphatemia is a particular problem among patients who are on both calcium-containing phosphate binders and active vitamin D analogs. In such patients who develop hypercalcemia, the dose of the calcium-containing phosphate binder should be decreased [
         <a href="#rid14">
          14
         </a>
         ] (see
         <a class="local">
          'Specific treatment'
         </a>
         above). In addition, the dose of active vitamin D analogs should be lowered or discontinued until calcium levels return to normal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Careful monitoring of the serum calcium concentration is essential with the chronic administration of calcium, particularly in patients on hemodialysis, where the dialysate calcium concentration can vary and therefore impact the ability to administer calcium-containing phosphate binders. (See
         <a class="local">
          'Monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As noted above however, even in the absence of hypercalcemia, a positive calcium balance, which is generally not detectable without careful balance studies, could increase the risk of vascular calcification. (See
         <a class="local">
          'Phosphate binders'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other agents
         </strong>
         – Other agents include
         <a class="drug drug_general" data-topicid="91795" href="/z/d/drug information/91795.html" rel="external">
          sucroferric oxyhydroxide
         </a>
         ,
         <a class="drug drug_general" data-topicid="96959" href="/z/d/drug information/96959.html" rel="external">
          ferric citrate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9696" href="/z/d/drug information/9696.html" rel="external">
          nicotinamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8499" href="/z/d/drug information/8499.html" rel="external">
          aluminum hydroxide
         </a>
         , and
         <a class="drug drug_general" data-topicid="8829" href="/z/d/drug information/8829.html" rel="external">
          calcium citrate
         </a>
         . We generally do not use these agents, either because of high cost, lack of efficacy, or concern over adverse effects.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Sucroferric oxyhydroxide
         </strong>
         <strong>
          (Velphoro)
         </strong>
         –
         <a class="drug drug_general" data-topicid="91795" href="/z/d/drug information/91795.html" rel="external">
          Sucroferric oxyhydroxide
         </a>
         is a chewable phosphate binder for patients with eGFR &lt;15 mL/min/1.73 m
         <sup>
          2
         </sup>
         [
         <a href="#rid103">
          103
         </a>
         ]. Sucroferric oxyhydroxide appears to be comparable with
         <a class="drug drug_general" data-topicid="10261" href="/z/d/drug information/10261.html" rel="external">
          sevelamer
         </a>
         in efficacy and safety and may be associated with a lower pill burden [
         <a href="#rid104">
          104,105
         </a>
         ]. Adverse effects are primarily gastrointestinal (diarrhea, nausea, abnormal product taste, constipation, and vomiting).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The starting dose of
         <a class="drug drug_general" data-topicid="91795" href="/z/d/drug information/91795.html" rel="external">
          sucroferric oxyhydroxide
         </a>
         is 2.5 g three times daily with meals or, if dosing is expressed in terms of elemental iron, 500 mg three times daily with meals. The majority of iron from sucroferric oxyhydroxide is not systemically absorbed, although small increases in transferrin saturation and ferritin have been observed with use [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ferric citrate
         </strong>
         <strong>
          –
         </strong>
         <a class="drug drug_general" data-topicid="96959" href="/z/d/drug information/96959.html" rel="external">
          Ferric citrate
         </a>
         is effective in reducing serum phosphate concentration by approximately the same degree as other phosphate binders [
         <a href="#rid35">
          35,107-109
         </a>
         ]. In addition, ferric citrate raises hemoglobin, serum iron, transferrin saturation, and ferritin. Patients on dialysis who take ferric citrate also may be receiving parenteral iron as part of an anemia management regimen; serum iron, transferrin saturation, and ferritin should be carefully monitored in such patients to avoid iron overload.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Citrate has been shown to enhance the absorption of aluminum, which increases the risk of aluminum toxicity. Because of this, some have recommended avoidance of all citrate-containing products in patients with CKD or who are on dialysis. However, in one trial of patients on maintenance dialysis, there was no aluminum toxicity noted among recipients of
         <a class="drug drug_general" data-topicid="96959" href="/z/d/drug information/96959.html" rel="external">
          ferric citrate
         </a>
         [
         <a href="#rid107">
          107
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Nicotinamide
         </strong>
         <strong>
          –
         </strong>
         We do not use
         <a class="drug drug_general" data-topicid="9696" href="/z/d/drug information/9696.html" rel="external">
          nicotinamide
         </a>
         to reduce phosphate levels in patients with CKD. Nicotinamide, a metabolite of nicotinic acid (niacin, vitamin B3), may lower serum phosphate by reducing gastrointestinal tract phosphate absorption [
         <a href="#rid108">
          108,109
         </a>
         ]. However, randomized trials examining nicotinamide as a treatment to lower phosphate in patients with nondialysis CKD and patients on dialysis have demonstrated limited efficacy, poor tolerance, and some safety concerns [
         <a href="#rid110">
          110,111
         </a>
         ]. For example, in a randomized trial that included over 700 patients on hemodialysis who were using phosphate binders, nicotinamide as add-on therapy lowered phosphate levels compared with placebo at 24 weeks, but this effect was not maintained at 52 weeks of follow-up [
         <a href="#rid111">
          111
         </a>
         ]. In addition, nicotinamide therapy was associated with higher rates of side effects, including diarrhea, pruritus, and thrombocytopenia.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Aluminum hydroxide
         </strong>
         <strong>
          –
         </strong>
         We do not use
         <a class="drug drug_general" data-topicid="8499" href="/z/d/drug information/8499.html" rel="external">
          aluminum hydroxide
         </a>
         in patients with CKD. Aluminum hydroxide is effective at controlling serum phosphorus, but the safety of aluminum-based phosphate binders in CKD has not been established. Excess aluminum exposure in CKD can result in aluminum toxicity. The major manifestations of aluminum toxicity are vitamin D-resistant osteomalacia, microcytic anemia, bone and muscle pain, and dementia. (See
         <a class="medical medical_review" href="/z/d/html/1839.html" rel="external">
          "Aluminum toxicity in chronic kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Calcium citrate
         </strong>
         <strong>
          –
         </strong>
         <a class="drug drug_general" data-topicid="8829" href="/z/d/drug information/8829.html" rel="external">
          Calcium citrate
         </a>
         has been used as a phosphate binder. Calcium citrate should be avoided in all patients with CKD since citrate can markedly increase intestinal aluminum absorption [
         <a href="#rid112">
          112,113
         </a>
         ]. The use of calcium citrate has been associated with aluminum neurotoxicity and the rapid onset of symptomatic osteomalacia [
         <a href="#rid114">
          114
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1839.html" rel="external">
          "Aluminum toxicity in chronic kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Citrate appears to enhance aluminum absorption both by keeping aluminum soluble (via the formation of aluminum citrate) in the intestinal lumen and by complexing with luminal calcium [
         <a href="#rid112">
          112,113
         </a>
         ]. The ensuing decrease in free calcium increases permeability of tight junctions between cells, which can markedly enhance passive aluminum absorption  (
         <a class="graphic graphic_figure graphicRef55777" href="/z/d/graphic/55777.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid112">
          112,113
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2622639543">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110749.html" rel="external">
          "Society guideline links: Chronic kidney disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring serum phosphate
         </strong>
         – In patients with estimated glomerular filtration rates (eGFR) &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         , we recommend monitoring serum phosphate, calcium, intact parathyroid hormone (iPTH), and 25-hydroxyvitamin D levels. The frequency of monitoring depends on the eGFR as outlined above. (See
         <a class="local">
          'Monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rationale for treatment
         </strong>
         – We suggest treating hyperphosphatemia in patients with chronic kidney disease (CKD) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). While high phosphate levels are shown to be associated with increased mortality in patients with CKD, the specific interventions suggested below that lower phosphate levels in most patients have not been shown to improve mortality or other clinical outcomes. (See
         <a class="local">
          'Treatment approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment thresholds
         </strong>
         – For patients with nondialysis CKD, we treat phosphate values that are persistently and progressively higher than normal (ie, 4.5 mg/dL), while, for patients on dialysis, we treat phosphate concentrations that are persistently &gt;5.5 mg/dL. These somewhat arbitrary thresholds are those that have been shown to be associated with mortality in observational studies. (See
         <a class="local">
          'Treatment approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dietary phosphate restriction
         </strong>
         – Our treatment approach begins with dietary phosphate restriction of 900 mg/day. The patient should be encouraged to avoid unnecessary dietary phosphate while maintaining the intake of high-biologic-value sources of protein. (See
         <a class="local">
          'Phosphate restriction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phosphate binders
         </strong>
         – If hyperphosphatemia persists with dietary restriction, we administer phosphate binders. However, alternative approaches are also reasonable:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Many experts do not use phosphate binders among patients with nondialysis CKD, since clinically relevant benefits have not been demonstrated.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other experts prescribe phosphate binders simultaneously with phosphate restriction in patients on dialysis. (See
         <a class="local">
          'Phosphate binders'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preference for non-calcium-containing binders
         </strong>
         – When phosphate binders are prescribed, for most patients we suggest non-calcium-containing binders (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Studies have suggested lower mortality associated with the use of non-calcium-containing binders compared with calcium-containing binders. However, the increased cost and restricted availability of these agents make calcium-containing binders an acceptable alternative in some circumstances. (See
         <a class="local">
          'Phosphate binders'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Refractory hyperphosphatemia
         </strong>
         – For refractory hyperphosphatemia, extended or increased hemodialysis is effective in lowering phosphate; however, this is not a practical option for many patients. Such patients may benefit from a modification of treatment of hyperparathyroidism. In adequately dialyzed patients who have serum phosphate levels persistently &gt;5.5 mg/dL despite dietary restriction, optimal treatment of hyperparathyroidism, and the appropriate use of phosphate binders, we suggest treatment with
         <a class="drug drug_general" data-topicid="122582" href="/z/d/drug information/122582.html" rel="external">
          tenapanor
         </a>
         and phosphate binders rather than phosphate binders alone (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). However, some experts use higher levels of serum phosphate as a threshold for tenapanor add-on therapy. (See
         <a class="local">
          'Refractory hyperphosphatemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H346555665">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Robert E Cronin, MD, and Michael Berkoben, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Slatopolsky E, Robson AM, Elkan I, Bricker NS. Control of phosphate excretion in uremic man. J Clin Invest 1968; 47:1865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tonelli M. Serum phosphorus in people with chronic kidney disease: you are what you eat. Kidney Int 2013; 84:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15:2208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Block G, Port FK. Calcium phosphate metabolism and cardiovascular disease in patients with chronic kidney disease. Semin Dial 2003; 16:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marco MP, Craver L, Betriu A, et al. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int Suppl 2003; :S111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, et al. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis 2005; 46:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmer SC, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011; 305:1119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int 2017; 92:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; :S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emmett M. A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. Kidney Int Suppl 2004; :S25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman EA. An introduction to phosphate binders for the treatment of hyperphosphatemia in patients with chronic kidney disease. Kidney Int Suppl 2005; :S2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Outcomes associated with serum phosphorus level in males with non-dialysis dependent chronic kidney disease. Clin Nephrol 2010; 73:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voormolen N, Noordzij M, Grootendorst DC, et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007; 22:2909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eddington H, Hoefield R, Sinha S, et al. Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol 2010; 5:2251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magagnoli L, Cozzolino M, Caskey FJ, et al. Association between CKD-MBD and mortality in older patients with advanced CKD-results from the EQUAL study. Nephrol Dial Transplant 2023; 38:2562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167:879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tonelli M, Sacks F, Pfeffer M, et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112:2627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehrotra R, Peralta CA, Chen SC, et al. No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease. Kidney Int 2013; 84:989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menon V, Greene T, Pereira AA, et al. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am J Kidney Dis 2005; 46:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23:1407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chue CD, Townend JN, Moody WE, et al. Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol 2013; 24:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toussaint ND, Pedagogos E, Lioufas NM, et al. A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). J Am Soc Nephrol 2020; 31:2653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jindal K, Chan CT, Deziel C, et al. Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 2006; 17:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uribarri J, Calvo MS. Hidden sources of phosphorus in the typical American diet: does it matter in nephrology? Semin Dial 2003; 16:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan C, Sayre SS, Leon JB, et al. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial. JAMA 2009; 301:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isakova T, Gutiérrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009; 20:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cannata-Andía JB, Fernández-Martín JL, Locatelli F, et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int 2013; 84:998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Streja E, Lau WL, Goldstein L, et al. Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients. Kidney Int Suppl (2011) 2013; 3:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King AJ, Siegel M, He Y, et al. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med 2018; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo H, Feng J, Zhang Y, et al. Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: A systematic review and meta-analysis of randomized placebo-controlled trials. Ther Apher Dial 2023; 27:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Block GA, Rosenbaum DP, Yan A, Chertow GM. Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial. J Am Soc Nephrol 2019; 30:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Block GA, Bleyer AJ, Silva AL, et al. Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM). Kidney360 2021; 2:1600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pergola PE, Rosenbaum DP, Yang Y, Chertow GM. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY). J Am Soc Nephrol 2021; 32:1465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukagawa M, Urano N, Ikejiri K, et al. Tenapanor for the Treatment of Hyperphosphatemia in Japanese Hemodialysis Patients: A Randomized Phase 3 Monotherapy Study With an Up-titration Regimen. Am J Kidney Dis 2023; 82:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nitta K, Itoyama S, Ikejiri K, et al. Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia. Kidney Int Rep 2023; 8:2243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silva AL, Chertow GM, Hernandez GT, et al. Tenapanor Improves Long-Term Control of Hyperphosphatemia in Patients Receiving Maintenance Dialysis: the NORMALIZE Study. Kidney360 2023; 4:1580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007; 72:1255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selamet U, Tighiouart H, Sarnak MJ, et al. Relationship of dietary phosphate intake with risk of end-stage renal disease and mortality in chronic kidney disease stages 3-5: The Modification of Diet in Renal Disease Study. Kidney Int 2016; 89:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calvo MS, Uribarri J. Contributions to total phosphorus intake: all sources considered. Semin Dial 2013; 26:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byrne FN, Gillman BA, Kiely M, et al. Pilot Randomized Controlled Trial of a Standard Versus a Modified Low-Phosphorus Diet in Hemodialysis Patients. Kidney Int Rep 2020; 5:1945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moorthi RN, Armstrong CL, Janda K, et al. The effect of a diet containing 70% protein from plants on mineral metabolism and musculoskeletal health in chronic kidney disease. Am J Nephrol 2014; 40:582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lynch KE, Lynch R, Curhan GC, Brunelli SM. Prescribed dietary phosphate restriction and survival among hemodialysis patients. Clin J Am Soc Nephrol 2011; 6:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Iorio B, Bellasi A, Russo D, INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012; 7:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Iorio B, Molony D, Bell C, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 2013; 62:771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadek T, Mazouz H, Bahloul H, et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol Dial Transplant 2003; 18:582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68:1815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72:1130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tonelli M, Wiebe N, Culleton B, et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007; 22:2856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Saudi Med J 2004; 25:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           St Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008; 51:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson R, Zhang P, Smyth M, Pratt R. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Curr Med Res Opin 2009; 25:3021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013; 382:1268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel L, Bernard LM, Elder GJ. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials. Clin J Am Soc Nephrol 2016; 11:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spoendlin J, Paik JM, Tsacogianis T, et al. Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis. JAMA Intern Med 2019; 179:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chertow GM, Raggi P, Chasan-Taber S, et al. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004; 19:1489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill KM, Martin BR, Wastney ME, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int 2013; 83:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evenepoel P, Wolf M. A balanced view of calcium and phosphate homeostasis in chronic kidney disease. Kidney Int 2013; 83:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiller LR, Santa Ana CA, Sheikh MS, et al. Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med 1989; 320:1110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delmez J, Block G, Robertson J, et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007; 68:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldberg DI, Dillon MA, Slatopolsky EA, et al. Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 1998; 13:2303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 1999; 55:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chertow GM, Dillon M, Burke SK, et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 1999; 51:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999; 33:694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogata H, Koiwa F, Shishido K, Kinugasa E. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management. Ther Apher Dial 2005; 9:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer D, Cline K, Plone MA, et al. Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing. Am J Kidney Dis 2006; 48:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 2008; 3:1125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manns B, Stevens L, Miskulin D, et al. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 2004; 66:1239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manns B, Klarenbach S, Lee H, et al. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 2007; 22:2867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joy MS, Finn WF, LAM-302 Study Group. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003; 42:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutchison AJ, Speake M, Al-Baaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant 2004; 19:1902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finn WF, Joy MS, Hladik G, Lanthanum Study Group. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 2004; 62:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Behets GJ, Verberckmoes SC, D'Haese PC, De Broe ME. Lanthanum carbonate: a new phosphate binder. Curr Opin Nephrol Hypertens 2004; 13:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutchison AJ, Maes B, Vanwalleghem J, et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005; 100:c8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiang SS, Chen JB, Yang WC. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol 2005; 63:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finn WF, SPD 405-307 Lanthanum Study Group. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 2006; 65:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Persy VP, Behets GJ, Bervoets AR, et al. Lanthanum: a safe phosphate binder. Semin Dial 2006; 19:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sprague SM, Abboud H, Qiu P, et al. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol 2009; 4:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003; :S73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freemont T, Malluche HH. Utilization of bone histomorphometry in renal osteodystrophy: demonstration of a new approach using data from a prospective study of lanthanum carbonate. Clin Nephrol 2005; 63:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altmann P, Barnett ME, Finn WF, SPD405-307 Lanthanum Carbonate Study Group. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int 2007; 71:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehrotra R, Martin KJ, Fishbane S, et al. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol 2008; 3:1437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fournier A, Morinière P, Ben Hamida F, et al. Use of alkaline calcium salts as phosphate binder in uremic patients. Kidney Int Suppl 1992; 38:S50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slatopolsky E, Weerts C, Lopez-Hilker S, et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986; 315:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slatopolsky E, Weerts C, Norwood K, et al. Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int 1989; 36:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mai ML, Emmett M, Sheikh MS, et al. Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 1989; 36:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delmez JA, Tindira CA, Windus DW, et al. Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 1992; 3:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morinière P, Djerad M, Boudailliez B, et al. Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Comparable efficacy for half the dose of elemental calcium given as acetate without lower incidence of hypercalcemia. Nephron 1992; 60:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meric F, Yap P, Bia MJ. Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy. Am J Kidney Dis 1990; 16:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurz P, Monier-Faugere MC, Bognar B, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342:1478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35:1226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15:2857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ewence AE, Bootman M, Roderick HL, et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res 2008; 103:e28.
          </a>
         </li>
         <li class="breakAll">
          http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails (Accessed on February 28, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wüthrich RP, Chonchol M, Covic A, et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 2013; 8:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Floege J, Covic AC, Ketteler M, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int 2014; 86:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Locatelli F, Del Vecchio L. Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients? J Nephrol 2017; 30:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Buren PN, Lewis JB, Dwyer JP, et al. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. Am J Kidney Dis 2015; 66:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller D, Mehling H, Otto B, et al. Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients. Clin J Am Soc Nephrol 2007; 2:1249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng SC, Young DO, Huang Y, et al. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:1131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ix JH, Isakova T, Larive B, et al. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial. J Am Soc Nephrol 2019; 30:1096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ketteler M, Wiecek A, Rosenkranz AR, et al. Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial. Nephrol Dial Transplant 2023; 38:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molitoris BA, Froment DH, Mackenzie TA, et al. Citrate: a major factor in the toxicity of orally administered aluminum compounds. Kidney Int 1989; 36:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nolan CR, Califano JR, Butzin CA. Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int 1990; 38:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirschbaum BB, Schoolwerth AC. Acute Aluminum Toxicity Associated With Oral Citrate and Aluminum-Containing Antacids. Am J Med Sci 1989; 297:9.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1942 Version 61.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5666116" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Control of phosphate excretion in uremic man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17091124" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24172733" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Serum phosphorus in people with chronic kidney disease: you are what you eat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15486872" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9531176" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15284307" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12641878" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Calcium phosphate metabolism and cardiovascular disease in patients with chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12753279" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15983959" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Mild hyperphosphatemia and mortality in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21406649" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28646995" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19644521" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14520607" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15296504" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A comparison of clinically useful phosphorus binders for patients with chronic kidney failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15954946" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : An introduction to phosphate binders for the treatment of hyperphosphatemia in patients with chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15615819" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Serum phosphate levels and mortality risk among people with chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20353734" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Outcomes associated with serum phosphorus level in males with non-dialysis dependent chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17517792" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20688884" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Serum phosphate and mortality in patients with chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37230954" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Association between CKD-MBD and mortality in older patients with advanced CKD-results from the EQUAL study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17502528" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16246962" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Relation between serum phosphate level and cardiovascular event rate in people with coronary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23615501" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16129207" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Relationship of phosphorus and calcium-phosphorus product with mortality in CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22822075" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Effects of phosphate binders in moderate CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23599381" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Cardiovascular effects of sevelamer in stage 3 CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32917784" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16497879" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12753675" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Hidden sources of phosphorus in the typical American diet: does it matter in nephrology?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19211470" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19092121" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Phosphorus binders and survival on hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23823605" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Use of phosphate-binding agents is associated with a lower risk of mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25019031" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30158152" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37349983" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: A systematic review and meta-analysis of randomized placebo-controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30846557" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35372979" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33766811" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37330134" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Tenapanor for the Treatment of Hyperphosphatemia in Japanese Hemodialysis Patients: A Randomized Phase 3 Monotherapy Study With an Up-titration Regimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38025211" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37853560" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Tenapanor Improves Long-Term Control of Hyperphosphatemia in Patients Receiving Maintenance Dialysis: the NORMALIZE Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17805238" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26422502" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Relationship of dietary phosphate intake with risk of end-stage renal disease and mortality in chronic kidney disease stages 3-5: The Modification of Diet in Renal Disease Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23278245" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Contributions to total phosphorus intake: all sources considered.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33163715" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Pilot Randomized Controlled Trial of a Standard Versus a Modified Low-Phosphorus Diet in Hemodialysis Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25613675" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The effect of a diet containing 70% protein from plants on mineral metabolism and musculoskeletal health in chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21148246" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Prescribed dietary phosphate restriction and survival among hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22241819" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Mortality in kidney disease patients treated with phosphate binders: a randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23684755" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12081584" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12584283" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16164659" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17200680" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17728707" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17906326" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15195212" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18295060" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19845495" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23870817" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26668024" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31058913" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15102961" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Determinants of progressive vascular calcification in haemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23254903" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23633052" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : A balanced view of calcium and phosphate homeostasis in chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2710173" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Effect of the time of administration of calcium acetate on phosphorus binding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18184521" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9002531" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9761513" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9893140" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9988142" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10196011" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15828900" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16931217" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18450923" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15327423" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17595182" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Economic evaluation of sevelamer in patients with end-stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12830461" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15199195" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15481851" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15199290" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Lanthanum carbonate: a new phosphate binder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15809508" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15960148" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16550750" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16689967" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Lanthanum: a safe phosphate binder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19056618" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12753271" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15730056" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Utilization of bone histomorphometry in renal osteodystrophy: demonstration of a new approach using data from a prospective study of lanthanum carbonate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17035945" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18579668" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1405382" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Use of alkaline calcium salts as phosphate binder in uremic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3724805" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2615197" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2811066" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Calcium acetate, an effective phosphorus binder in patients with renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1391713" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Calcium acetate as a phosphorus binder in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1738415" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Comparable efficacy for half the dose of elemental calcium given as acetate without lower incidence of hypercalcemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2239937" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7996807" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Evidence for abnormal calcium homeostasis in patients with adynamic bone disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10816185" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10845841" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15504939" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18669918" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18669918" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23124782" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24646861" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28717990" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25958079" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17913971" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18385391" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31085679" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35751625" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2689754" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Citrate: a major factor in the toxicity of orally administered aluminum compounds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2266679" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Influence of calcium acetate or calcium citrate on intestinal aluminum absorption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2913801" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Acute Aluminum Toxicity Associated With Oral Citrate and Aluminum-Containing Antacids
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
